Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Picard Medical, Inc. ( (PMI) ) just unveiled an update.
On March 12, 2026, Picard Medical, Inc. announced it would host a webcasted Annual Business Update on March 25, 2026, following the filing of its Form 10-K for the fiscal year ended December 31, 2025. The virtual event will review fiscal year and fourth quarter 2025 financial results and provide a business update covering operational progress, commercial activity, and strategic priorities.
The webcast will feature management presentations as well as insights from leading cardiothoracic surgeons on the SynCardia Total Artificial Heart and the evolving artificial heart landscape, along with a patient testimonial. The inclusion of clinical key opinion leaders and real-world patient experience underscores Picard Medical’s effort to reinforce SynCardia’s clinical relevance and market leadership as it advances its next-generation, fully implantable Emperor artificial heart platform.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., parent of SynCardia Systems LLC, operates in the medical device sector focused on advanced cardiac support technologies. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, the only commercially available artificial heart approved by both the U.S. FDA and Health Canada, with more than 2,100 implants across 27 countries to treat end-stage heart failure.
The company’s SynCardia Total Artificial Heart is an implantable system that fully replaces the circulatory function of a failing human heart. Positioned as the most widely used and extensively studied artificial heart globally, Picard Medical targets hospitals and cardiac centers treating patients with end-stage heart failure in the U.S., Canada, and international markets.
Average Trading Volume: 812,532
Technical Sentiment Signal: Strong Sell
For detailed information about PMI stock, go to TipRanks’ Stock Analysis page.